Extension Statement for CONSORT-C: Improving Reporting Standards and Influence in Pediatric and Adolescent Research - Scorecard - MDSpire

Extension Statement for CONSORT-C: Improving Reporting Standards and Influence in Pediatric and Adolescent Research

  • By

  • Ami Baba

  • Maureen Smith

  • Beth K. Potter

  • An-Wen Chan

  • David Moher

  • Alene Toulany

  • Amanda Doherty-Kirby

  • Begonya Nafria Escalera

  • Catherine Stratton

  • Chris Gale

  • Colin Macarthur

  • Diane Purper-Ouakil

  • Edmund Juszczak

  • Eyal Cohen

  • Giorgio Reggiardo

  • Jennifer Preston

  • Jérémie F. Cohen

  • Julia Upton

  • Karel Allegaert

  • Katelynn Boerner

  • Kayur Mehta

  • Kim An Nguyen

  • Kimberly Courtney

  • Lisa Hartling

  • Menelaos Konstantinidis

  • Michal Odermarsky

  • Nancy J. Butcher

  • Niina Kolehmainen

  • Patricia E. Longmuir

  • Peter J. Gill

  • Piet Leroy

  • Reinhard Feneberg

  • Ramesh Poluru

  • Shaun K. Morris

  • Stefan J. Friedrichsdorf

  • Tanya Chute Nagy

  • Terry P. Klassen

  • Thierry Lacaze-Masmonteil

  • Wes Onland

  • Martin Offringa

  • April 1, 2026

  • 0 min

Share

Clinical Scorecard: Extension Statement for CONSORT-C: Improving Reporting Standards and Influence in Pediatric and Adolescent Research

At a Glance

CategoryDetail
ConditionRandomized controlled trials (RCTs) in pediatric and adolescent populations
Key MechanismsDevelopment of CONSORT-C 2026 extension to improve reporting quality and transparency specific to pediatric RCTs
Target PopulationNewborns, infants, children, and adolescents aged 0-19 years
Care SettingClinical research settings conducting pediatric and adolescent RCTs

Key Highlights

  • Pediatric RCTs are underrepresented and often suffer from suboptimal reporting, limiting evidence quality.
  • CONSORT-C 2026 provides harmonized, evidence-based reporting guidance tailored to the unique needs of pediatric trials.
  • Young people and family caregivers were actively involved in the development process to ensure relevance and applicability.

Guideline-Based Recommendations

Diagnosis

  • Not applicable—focus is on reporting standards for pediatric RCTs rather than diagnosis.

Management

  • Use CONSORT-C 2026 checklist to ensure comprehensive and transparent reporting of pediatric RCTs.
  • Report critical trial elements including consent/assent processes, comparator interventions, randomization, blinding, pain and harms prevention, missing data sources, and age-appropriate outcomes.

Monitoring & Follow-up

  • Monitor adherence to CONSORT-C 2026 guidelines to improve reporting quality and reduce research waste.

Risks

  • Poor reporting in pediatric RCTs risks misinterpretation, limits critical appraisal, and impedes evidence-based pediatric care.

Patient & Prescribing Data

Newborns, infants, children, and adolescents aged 0-19 years involved in RCTs

Not applicable—article focuses on reporting standards rather than treatment data.

Clinical Best Practices

  • Involve pediatric patients and family caregivers in trial design and reporting to enhance relevance and clarity.
  • Adopt age-appropriate trial interventions and formulations considering biological and developmental differences.
  • Ensure transparent reporting of consent and assent processes respecting jurisdictional variations.
  • Report trial procedures addressing pain and harms prevention specific to pediatric populations.
  • Use international consensus-based guidelines (CONSORT-C 2026) to standardize pediatric RCT reporting.

References

Original Source(s)

Related Content